From: Models of breast cancer: is merging human and animal models the future?
Human breast cancer xenograft model | Description | Reference |
---|---|---|
MCF-7 | Breast adenocarcinoma cell line, oestrogen receptor-positive | [37] |
MCF-7/6 | Oestrogen sensitive | [38] |
MCF-7 BAG | Immunodeficient xenograft model | [39] |
MCF-7/hVEGF | hVEGF overexpressing | Â |
MCF-7-TAM LT | Long-term tamoxifen-stimulated breast tumour model | [40] |
MCF-7/neu | Overexpressing oncogene neu | [41] |
MCF-7-MIII | Oestrogen sensitive | [42] |
MCF-7Ca | Transfected with human aromatase gene | [43] |
MT2 | MCF-7 tamoxifen-stimulated tumour with Asp351Tyr mutant oestrogen receptor | [44] |
MT2 TAM | MCF-7-derived tumour serially passaged with tamoxifen | [40] |
MT-1 | Oestrogen and progesterone receptor-negative in nude rats | [45] |
MT-3 | Oestrogen receptor-negative | [45] |
LY2 | Anti-oestrogen-resistant variant of MCF-7 | [46] |
UMB-1Ca | Oestrogen-independent variant of MCF-7 | [47] |
MDA-MB-231 | Oestrogen independent | [48] |
MDA-MD-231 BAG | Immunodeficient xenograft model | [39] |
MDA-MB-361 | Brain metastasis-derived breast adenocarcinoma cell line | [49] |
MDA-MB-435 | Oestrogen receptor-negative | [48] |
MDA-MB-435A | Ascites model | [50] |
MDA-MB-435S | Spindle-shaped strain of parent line | [51] |
MDA-MD-435 BAG | Immunodeficient xenograft model | [39] |
MDA-MB-453 BAG | Fibroblast growth factor receptor overexpressing | [39] |
MDA-453/LCC6 | Â | [52] |
MDA-MB-468 | Oestrogen receptor-negative metastasis-derived cell line | [49] |
MDA-MB-453 | Breast adenocarcinoma cell line | [53] |
MCF10AT | Preneoplastic and proliferative model; nontumourigenic | [54] |
MCF10AneoN | Transfected with neomycin-resistance gene | [55] |
MCF10AneoT | T24-Ha-ras-transformed derivative of MCF10A | [55] |
MCF10DCIS.com | Comedo ductal carcinoma in situ | [56] |
MC-2 | Â | [57] |
MC-5 | Â | [57] |
MC-18 | Â | [57] |
SK-BR3 | Breast adenocarcinoma cell line that overexpresses oncogenic protein p185HER2; oestrogen receptor-negative | [58] |
SK-BR3/hVEGF | VEGF overexpressing cell line | [58] |
BT-20 | Oestrogen receptor-negative | [37] |
BT-474 | Erb2 overexpressing breast tumour | [59] |
ZR-75-1 | Oestrogen-dependent breast carcinoma | [60] |
SUM149 | Inflammmatory breast cancer cell line | [61] |
SUM159PT | Oestrogen independent | [62] |
T47D | Oestrogen receptor-positive | [63] |
T47D-E2 | Tamoxifen naïve tumour | [63] |
KPL-1 | Oestrogen receptor-positive | [64] |
KPL-4 | Oestrogen receptor-negative | [65] |
MaTu | Oestrogen receptor-negative solid human mammary carcinoma cell line | [45] |
MC4000 | Oestrogen receptor-negative | [45] |
HT-39 | Oestrogen receptor-negative | [66] |
HX99 | Â | [67] |
T61 | Oestrogen receptor-positive ductal carcinoma | [68] |
B37 | Â | [69] |
BO | Oestrogen receptor-positive | [70] |
Br10 | Â | [71] |
SE | Â | [71] |
WIBC-9 | Inflammmatory breast cancer cell line | [57] |
Met-1 | Metastatic breast cancer cell line | Â |
MAXF401 | Â | [72] |
MX-1 | Â | [73] |
MAXF 499 | Solid ductal | [74] |
NCI/ADR or MCF-7/ADR | Multidrug-resistant MCF-7 cell line that overexpresses P-glycoprotein | [75] |
4296 | Oestrogen receptor-positive | [76] |
4049 | Oestrogen receptor-negative | [76] |
4151 | Â | [75] |
4134 | Â | [75] |
3366 | Â | [77] |
4000 | Â | [77] |
CAL51 | Metastatic model of adenocarcinoma | [78] |
MA-11 | Oestrogen and progesterone negative receptor in nude rats | [79] |
H31 | Â | [80] |
MARY-X | Inflammatory breast cancer model | [81] |
HBT 3477 | Adenocarcinoma | [82] |
Hs578T | Carcinosarcoma derived, epithelial in origin | [82] |
C8161 | Breast cancer line with high levels of spontaneous metastasis | [83] |
M24met | Breast cancer line with high levels of spontaneous metastasis | [83] |
CaMa 15 | Primary infiltrating ductal breast carcinoma | [37] |
MaNo 4 | Medullary breast carcinoma | [37] |
GI-101 | Metastatic breast tumour line | [25] |
UISO-BCA-NMT-18 | Primary breast carcinoma | [84] |